ArticleNature medicine2020
Dynamic imaging in patients with tuberculosis reveals heterogeneous drug exposures in pulmonary lesions.
Open access · greenAbstract readClinical Study
In one paragraph
Article in Nature medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 76 papers, 2 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
76citing papers in PubMed, 2 pooled it
2.3field-weighted citation impact, top 7% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
76 citing papers in PubMed, 2 syntheses or guidelines pooled it, 124 citations in OpenAlex.
- Systematic and quantitative analyses of hollow fiber model ofMicrobiology spectrum · 2026Pooled it
- A clinical practice guideline for tuberculous meningitis.The Lancet. Infectious diseases · 2026Guideline
- Insights From Spatiality: Accelerating Pharmaceutical Research Using Mass Spectrometry Imaging.Medicinal research reviews · 2026Review
- Nuclear medicine imaging to guide antibiotic therapy: an expert review.The British journal of radiology · 2026Review
- Article
- Divergent Evolution of Tuberculosis Lesions During Treatment: A Longitudinal CT-Based Analysis of Progression and Regression Patterns.Diagnostics (Basel, Switzerland) · 2026Article
- Mycobacterium tuberculosis transmission among child and adolescent contacts of people with pulmonary tuberculosis in Brazil: a multi-center prospective cohort study.BMC infectious diseases · 2025Observational
- Automated radiosynthesis of [EJNMMI radiopharmacy and chemistry · 2025Article
- Development of Co-Amorphous Systems for Inhalation Therapy-Part 2: In Silico Guided Co-Amorphous Rifampicin-Moxifloxacin and -Ethambutol Formulations.Pharmaceutics · 2025Article
- Improved Radiosynthesis of [ACS infectious diseases · 2025Article
- Factors associated with post-treatment resorption of lung cavities in individuals with first episodes of drug-sensitive cavitary pulmonary tuberculosis in China.BMC infectious diseases · 2025Article
- PET imaging of mycobacterial infection: transforming the pipeline for tuberculosis drug development.Npj imaging · 2025Review
- Review
- Proapoptotic Bcl-2 inhibitor as potential host directed therapy for pulmonary tuberculosis.Nature communications · 2025Article
- Diagnostic value of neutrophil-to-lymphocyte ratio, fibrinogen-to-albumin ratio and red blood cell distribution width in tuberculosis combined with other bacterial infections.BMC pulmonary medicine · 2025Article
- Fluoroquinolones and rifampin combination in the backdrop of heteroresistant tuberculosis.Antimicrobial agents and chemotherapy · 2025Article
- Targeted therapeutic drug monitoring identifies frequent under-dosing of TB drugs.The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease · 2025Article
- Leveraging insights from cancer to improve tuberculosis therapy.Trends in molecular medicine · 2025Article
- Examining effective monotherapy hypothesis for TB therapy failure and resistance emergence.The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease · 2024Article
- Proapoptotic Bcl-2 inhibitor as host directed therapy for pulmonary tuberculosis.Research square · 2024Article
16 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
21 authors at 5 institutions in 1 country.
Alvaro A OrdonezCenter for Infection and Inflammation Imaging Research, Johns Hopkins University School of Medicine, Baltimore, MD, USA.ORCID http://orcid.org/0000-0002-8571-0655
Hechuan WangCenter for Translational Medicine, University of Maryland School of Pharmacy, Baltimore, MD, USA.ORCID http://orcid.org/0000-0002-0792-7816
Gesham MagombedzeCenter for Infectious Diseases Research and Experimental Therapeutics, Baylor University Medical Center and Texas Tech University Health Sciences Center, Dallas, TX, USA.
Camilo A Ruiz-BedoyaCenter for Infection and Inflammation Imaging Research, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Shashikant SrivastavaCenter for Infectious Diseases Research and Experimental Therapeutics, Baylor University Medical Center and Texas Tech University Health Sciences Center, Dallas, TX, USA.
Allen ChenCenter for Infection and Inflammation Imaging Research, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Elizabeth W TuckerCenter for Infection and Inflammation Imaging Research, Johns Hopkins University School of Medicine, Baltimore, MD, USA.ORCID http://orcid.org/0000-0002-0971-3635
Michael E UrbanowskiCenter for Tuberculosis Research, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Lisa PieterseCenter for Infection and Inflammation Imaging Research, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
E Fabian CardozoVaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.ORCID http://orcid.org/0000-0001-8690-9896
Martin A LodgeRussell H. Morgan Department of Radiology and Radiological Sciences, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Maunank R ShahCenter for Tuberculosis Research, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Daniel P HoltRussell H. Morgan Department of Radiology and Radiological Sciences, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
William B MathewsRussell H. Morgan Department of Radiology and Radiological Sciences, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Robert F DannalsRussell H. Morgan Department of Radiology and Radiological Sciences, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Jogarao V S GobburuCenter for Translational Medicine, University of Maryland School of Pharmacy, Baltimore, MD, USA.
Charles A PeloquinInfectious Disease Pharmacokinetics Laboratory, Pharmacotherapy and Translational Research, University of Florida College of Pharmacy, Gainesville, FL, USA.
Steven P RoweRussell H. Morgan Department of Radiology and Radiological Sciences, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Tawanda GumboCenter for Infectious Diseases Research and Experimental Therapeutics, Baylor University Medical Center and Texas Tech University Health Sciences Center, Dallas, TX, USA.
Vijay D IvaturiCenter for Translational Medicine, University of Maryland School of Pharmacy, Baltimore, MD, USA.
Sanjay K JainCenter for Infection and Inflammation Imaging Research, Johns Hopkins University School of Medicine, Baltimore, MD, USA. sjain5@jhmi.edu.ORCID http://orcid.org/0000-0001-9620-7070
Johns Hopkins University · USTexas Tech University · USUniversity of Maryland, Baltimore · USFred Hutch Cancer Center · USUniversity of Florida · US
Funding
Novel Imaging Tracers for Rapid and Noninvasive Assessment of Bacterial InfectionR01EB020539 · NIBIB · JOHNS HOPKINS UNIVERSITY · PI JAIN, SANJAY · 2014 to 2018
$3.6MMolecular Imaging for Pulmonary Infections and InflammationR01HL131829 · NHLBI · JOHNS HOPKINS UNIVERSITY · PI JAIN, SANJAY · 2016 to 2018
$2.2MNovel Imaging and host-directed therapy in pediatric CNS TBK08AI139371 · NIAID · JOHNS HOPKINS UNIVERSITY · PI TUCKER, ELIZABETH WINANS · 2019 to 2023
$994kPreclinical modeling to study Tuberculous MeningitisR56AI145435 · NIAID · JOHNS HOPKINS UNIVERSITY · PI JAIN, SANJAY · 2019 to 2019
$839kNHLBI NIH HHS R01 HL131829NIAID NIH HHS K08 AI139371NIAID NIH HHS R56 AI145435NIBIB NIH HHS R01 EB020539
Abstract
Tuberculosis (TB) is the leading cause of death from a single infectious agent, requiring at least 6 months of multidrug treatment to achieve cure
Indexed as
AdultAnimalsAntitubercular AgentsBiological AvailabilityDrug Therapy, CombinationFemaleHumansLungMaleMycobacterium tuberculosisPositron Emission Tomography Computed TomographyRabbitsRifampinTissue DistributionTuberculosisTuberculosis, PulmonaryAntitubercular AgentsRifampin
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.